Tesamorelin is a growth hormone-releasing hormone analog. It does not directly provide growth hormone. Instead, it signals the pituitary to increase endogenous growth hormone release, which can then influence IGF-1 and downstream metabolic pathways.
Tesamorelin is clinically notable because it is one of the few peptides with a clear approved medical indication. It is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
In a 26-week clinical trial published in the New England Journal of Medicine, daily tesamorelin decreased visceral fat and improved lipid profiles in HIV-infected patients with abdominal fat accumulation.
That distinction is important: tesamorelin is not simply a “weight loss peptide.” Its strongest clinical identity is visceral adipose tissue reduction, especially in a specific medical population. Visceral fat is the fat stored around internal organs. It is metabolically different from subcutaneous fat and is more strongly associated with cardiometabolic risk.
This is why tesamorelin is often discussed in body-composition circles. People interested in abdominal fat reduction tend to focus on the compound because it targets a different axis than GLP-1s. GLP-1s mainly influence appetite and calorie intake. Tesamorelin works through GH-axis signaling.
However, GH-axis compounds need more caution than typical wellness marketing admits. Increasing GH and IGF-1 signaling can affect glucose, fluid retention, joint symptoms, carpal tunnel-like symptoms, and theoretical concerns around active malignancy risk. The Egrifta prescribing information includes warnings and contraindications, including pregnancy and malignancy-related considerations.
Tesamorelin is best understood as a precision peptide in body-composition research. Its strongest identity is not general weight loss, but visceral abdominal fat reduction through GH-axis signaling.
Unlike GLP-1 compounds that primarily influence appetite and food intake, tesamorelin works through growth hormone-releasing hormone activity. This makes it especially relevant in discussions around deeper abdominal fat, metabolic health, and body composition quality.
Its value comes from specificity. Tesamorelin targets a pathway connected to visceral fat, IGF-1 signaling, and metabolic regulation, making it one of the most clinically recognized peptides in the abdominal fat and recomposition category.
The clean takeaway is simple: tesamorelin is a GHRH analog known for its connection to visceral fat research, GH-axis signaling, and advanced body-composition support. It is not a casual fat burner. It is a targeted peptide with a clear clinical background and a strong place in metabolic and recomposition-focused research.